Freestone Grove Partners LP Ardelyx, Inc. Transaction History
Freestone Grove Partners LP
- $8.16 Trillion
- Q4 2024
A detailed history of Freestone Grove Partners LP transactions in Ardelyx, Inc. stock. As of the latest transaction made, Freestone Grove Partners LP holds 16,331 shares of ARDX stock, worth $103,865. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,331Holding current value
$103,865% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ARDX
# of Institutions
233Shares Held
150MCall Options Held
1.54MPut Options Held
3.08M-
Janus Henderson Group PLC London, X024.4MShares$155 Million0.07% of portfolio
-
Black Rock Inc. New York, NY17.6MShares$112 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.4MShares$91.3 Million0.0% of portfolio
-
State Street Corp Boston, MA11.6MShares$73.7 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C310.3MShares$65.8 Million0.06% of portfolio
About ARDELYX, INC.
- Ticker ARDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 154,636,000
- Market Cap $983M
- Description
- Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...